{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:22Z","timestamp":1790958682985,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jconrel.2021.12.027","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T01:31:51Z","timestamp":1640223111000},"page":"50-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"special_numbering":"C","title":["Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)"],"prefix":"10.1016","volume":"344","author":[{"given":"Hamideh","family":"Parhiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler E.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna","family":"Shahnawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco E.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Yadegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Marcos-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir V.","family":"Shuvaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Kiseleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Uhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieu","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Heyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir R.","family":"Muzykantov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.12.027_bb0005","first-page":"109","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0010","first-page":"330","article-title":"Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine","volume":"9","author":"Carlsson","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0015","first-page":"625","article-title":"Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0020","first-page":"1114","article-title":"Modified mRNA vaccines protect against zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0025","first-page":"1316","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0030","first-page":"165","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0035","first-page":"948","article-title":"Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin","volume":"20","author":"Karik\u00f3","year":"2012","journal-title":"Mol. Therap."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0040","first-page":"248","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0045","first-page":"106","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0050","series-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine \u2014 United States, December 2020, in, MMWR Morb Mortal Wkly Rep","first-page":"1922","author":"Oliver","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0055","series-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine \u2014 United States, December 2020, in, MMWR Morb Mortal Wkly Rep","first-page":"1653","author":"Oliver","year":"2021"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0060","first-page":"146","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0065","first-page":"4333","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0070","first-page":"3018","article-title":"Lipid nanoparticles potentiate CpG-Oligodeoxynucleotide-based vaccine for influenza virus","volume":"10","author":"Shirai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0075","first-page":"319","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0080","first-page":"26","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersdorfer","year":"2019","journal-title":"Mol. Ther. Nucleic. Acids"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0085","first-page":"1570","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0090","first-page":"8529","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0095","first-page":"6948","article-title":"Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation","volume":"134","author":"Chen","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0100","first-page":"161","article-title":"Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo","volume":"163","author":"Hood","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0105","article-title":"Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation","volume":"9","author":"Ferrer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0110","first-page":"1495","article-title":"Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions","volume":"13","author":"Brenner","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0115","first-page":"L379","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0120","first-page":"760","article-title":"Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders","volume":"63","author":"Montagne","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0125","first-page":"1425","article-title":"Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation","volume":"7","author":"Norman","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0130","first-page":"65s","article-title":"Immunotoxicity of nanoparticles","volume":"24","author":"Di Gioacchino","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0135","first-page":"404","article-title":"Targeted detoxification of selected reactive oxygen species in the vascular endothelium","volume":"331","author":"Shuvaev","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0140","first-page":"2684","article-title":"Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude","volume":"9","author":"Brenner","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0145","first-page":"2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0150","first-page":"10689","article-title":"Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction","volume":"274","author":"Chow","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0155","first-page":"3749","article-title":"Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product","volume":"162","author":"Hoshino","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0160","first-page":"20","article-title":"Tlr4: central component of the sole mammalian LPS sensor","volume":"12","author":"Beutler","year":"2000","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0165","first-page":"345","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0170","first-page":"589","article-title":"Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes","volume":"12","author":"Wibroe","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0175","first-page":"4105","article-title":"Depletion and reconstitution of macrophages in mice","author":"Weisser","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0180","series-title":"Mouse Models of Innate Immunity: Methods and Protocols","first-page":"101","article-title":"Depletion and reconstitution of macrophages in mice","author":"Kozicky","year":"2019"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0185","first-page":"603","article-title":"Molecular mechanisms of glucocorticoid action: what is important?","volume":"55","author":"Newton","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0190","first-page":"6274","article-title":"Jun N-terminal kinase\/stress-activated protein kinase (JNK\/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK\/SAPK","volume":"17","author":"Swantek","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0195","first-page":"391","article-title":"Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin\/tumor necrosis factor synthesis at separate points in the signaling pathway","volume":"172","author":"Han","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0200","first-page":"292","article-title":"Pioglitazone has anti-inflammatory effects in patients with type 2 diabetes","volume":"30","author":"Heli\u00f6vaara","year":"2007","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0205","first-page":"91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0210","article-title":"Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0215","first-page":"83","article-title":"Cholesterol metabolites alleviate injured liver function and decrease mortality in an LPS-induced mouse model","volume":"71","author":"Ning","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0220","first-page":"555","article-title":"Comparison of the TLR4\/NF\u03baB and NLRP3 signalling pathways in major organs of the mouse after intravenous injection of lipopolysaccharide","volume":"57","author":"Gong","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0225","first-page":"348","article-title":"Spatially controlled assembly of affinity ligand and enzyme cargo enables targeting ferritin nanocarriers to caveolae","volume":"185","author":"Shuvaev","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0230","first-page":"e1802373","article-title":"Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles","volume":"30","author":"Myerson","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0235","first-page":"113","article-title":"TNF and related molecules: trends in neuroscience and clinical applications","volume":"72","author":"Probert","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0240","first-page":"218","article-title":"Nervous tissue as an immune compartment: the dialect of the immune response in the CNS","volume":"15","author":"Fabry","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0245","first-page":"965","article-title":"Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells","volume":"76","author":"Carlos","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0250","first-page":"3405","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier","volume":"117","author":"Marcos-Contreras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0255","first-page":"36","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0260","first-page":"782","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0265","article-title":"Nanomedicines to deliver mRNA: state of the art and future perspectives","volume":"10","author":"G\u00f3mez-Aguado","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0270","series-title":"A Trial Investigating the Safety and Effects of Four BNT162 Vaccines against COVID-2019 in Healthy Adults","author":"BioNTech","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0275","series-title":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","author":"Moderna","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0280","series-title":"Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report, medRxiv","author":"Mulligan","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0285","first-page":"90","article-title":"Unintended effects of drug carriers: big issues of small particles","volume":"130","author":"Parhiz","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0290","first-page":"9","article-title":"Innate immune response induced by gene delivery vectors","volume":"354","author":"Sakurai","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0295","first-page":"247","article-title":"Immune activation by siRNA\/liposome complexes in mice is sequence- independent: lack of a role for toll-like receptor 3 signaling","volume":"24","author":"Kim","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2021.12.027_bb0300","first-page":"1020","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0305","first-page":"819","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0310","first-page":"14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0315","first-page":"E1941","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0320","first-page":"1434","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0325","first-page":"54","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0330","first-page":"301","article-title":"mRNA as novel technology for passive immunotherapy","volume":"76","author":"Schlake","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0335","first-page":"171","article-title":"Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment","volume":"18","author":"Abrams","year":"2010","journal-title":"Mol. Therap."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0340","first-page":"1415","article-title":"mRNA delivery for therapeutic anti-HER2 antibody expression in vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0345","first-page":"1904905","article-title":"Mild innate immune activation overrides efficient nanoparticle-mediated RNA delivery","volume":"32","author":"Lokugamage","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0350","first-page":"1002","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0355","first-page":"335","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0360","first-page":"4091","article-title":"Synthetic nucleic acid delivery systems: present and perspectives","volume":"58","author":"Draghici","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0365","first-page":"697","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0370","first-page":"1120","article-title":"The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes","volume":"9","author":"Sakurai","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0375","first-page":"299","article-title":"Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles","volume":"42","author":"Ohto","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2021.12.027_bb0380","first-page":"124","article-title":"Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome","volume":"13","author":"Walker","year":"2010","journal-title":"Curr. Opin. Drug. Discov. Devel."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921006805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921006805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:15:35Z","timestamp":1759162535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921006805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":76,"alternative-id":["S0168365921006805"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}